ECSP23076800A - Derivados de pirazolopiridina y sus usos - Google Patents
Derivados de pirazolopiridina y sus usosInfo
- Publication number
- ECSP23076800A ECSP23076800A ECSENADI202376800A ECDI202376800A ECSP23076800A EC SP23076800 A ECSP23076800 A EC SP23076800A EC SENADI202376800 A ECSENADI202376800 A EC SENADI202376800A EC DI202376800 A ECDI202376800 A EC DI202376800A EC SP23076800 A ECSP23076800 A EC SP23076800A
- Authority
- EC
- Ecuador
- Prior art keywords
- hemoglobinopathies
- beta
- expression
- pyrazolopyridine derivatives
- wiz
- Prior art date
Links
- 150000005229 pyrazolopyridines Chemical class 0.000 title 1
- 102100020716 Protein Wiz Human genes 0.000 abstract 2
- 101710186935 Protein Wiz Proteins 0.000 abstract 2
- 208000034737 hemoglobinopathy Diseases 0.000 abstract 2
- 208000018337 inherited hemoglobinopathy Diseases 0.000 abstract 2
- 208000019838 Blood disease Diseases 0.000 abstract 1
- 108010044495 Fetal Hemoglobin Proteins 0.000 abstract 1
- 208000018020 Sickle cell-beta-thalassemia disease syndrome Diseases 0.000 abstract 1
- 206010043391 Thalassaemia beta Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000014951 hematologic disease Diseases 0.000 abstract 1
- 208000018706 hematopoietic system disease Diseases 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000007056 sickle cell anemia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente divulgación se refiere a compuestos de Fórmula (I) y composiciones farmacéuticas y su uso en la reducción de los niveles de expresión de los Motivos de Dedos de Zinc Ampliamente Interespaciados (WIZ), o en la inducción de la expresión de la hemoglobina fetal (HbF), y en el tratamiento de trastornos de la sangre hereditarios (por ejemplo, hemoglobinopatías, por ejemplo, betahemoglobinopatías), tales como la enfermedad de células falciformes y betatalasemia.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163161139P | 2021-03-15 | 2021-03-15 | |
| US202163164130P | 2021-03-22 | 2021-03-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP23076800A true ECSP23076800A (es) | 2023-11-30 |
Family
ID=80819999
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202376800A ECSP23076800A (es) | 2021-03-15 | 2023-10-12 | Derivados de pirazolopiridina y sus usos |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US11787785B2 (es) |
| EP (1) | EP4308562A1 (es) |
| JP (2) | JP7659648B2 (es) |
| KR (1) | KR102902295B1 (es) |
| AU (1) | AU2022239950B2 (es) |
| CA (1) | CA3208951A1 (es) |
| CL (1) | CL2023002726A1 (es) |
| CO (1) | CO2023013486A2 (es) |
| CR (1) | CR20230486A (es) |
| DO (1) | DOP2023000188A (es) |
| EC (1) | ECSP23076800A (es) |
| IL (1) | IL305931A (es) |
| JO (1) | JOP20230218A1 (es) |
| MX (1) | MX2023010827A (es) |
| NZ (1) | NZ802195A (es) |
| PE (1) | PE20242203A1 (es) |
| PY (1) | PY2217419A (es) |
| TW (1) | TW202304900A (es) |
| UY (1) | UY39671A (es) |
| WO (1) | WO2022195454A1 (es) |
| ZA (1) | ZA202307290B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4308559A1 (en) * | 2021-03-15 | 2024-01-24 | Novartis AG | Benzisoxazole derivatives and uses thereof |
| UY39671A (es) | 2021-03-15 | 2022-10-31 | Novartis Ag | Derivados de pirazolopiridina y sus usos. |
| AR130961A1 (es) | 2022-11-04 | 2025-02-05 | Bristol Myers Squibb Co | Compuestos y su uso para el tratamiento de hemoglobinopatías |
| KR20260022448A (ko) * | 2023-06-15 | 2026-02-19 | 링크큐어 세라퓨틱스 | 디히드로피리미딘-2,4(1h,3h)-디온을 함유하는 폴리시클릭 유도체 및 이의 약학적 조성물, 이의 제조 방법 및 이의 용도 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2514733A1 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| EP1694328A4 (en) | 2003-12-02 | 2010-02-17 | Celgene Corp | METHOD AND COMPOSITIONS FOR THE TREATMENT AND SUPPLY OF HEMOGLOBINOPATHY AND ANEMIA |
| EP1604988A1 (en) | 2004-05-18 | 2005-12-14 | Sanofi-Aventis Deutschland GmbH | Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals |
| MY163114A (en) | 2008-04-28 | 2017-08-15 | Kyorin Seiyaku Kk | Cyclopentylacrylamide derivative |
| EP2165707A1 (en) * | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| PL2536706T3 (pl) * | 2010-02-11 | 2017-10-31 | Celgene Corp | Pochodne arylometoksyizoindoliny i zawierające je kompozycje oraz sposoby ich zastosowania |
| BR112015000675B1 (pt) | 2012-07-13 | 2022-07-12 | UCB Biopharma SRL | Derivados de imidazopiridina como moduladores da atividade de tnf |
| US9845308B2 (en) | 2014-11-05 | 2017-12-19 | Vitae Pharmaceuticals, Inc. | Isoindoline inhibitors of ROR-gamma |
| TWI793151B (zh) * | 2017-08-23 | 2023-02-21 | 瑞士商諾華公司 | 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途 |
| WO2019140387A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
| JP2020009513A (ja) * | 2018-07-10 | 2020-01-16 | キオクシア株式会社 | メモリシステム |
| AR116109A1 (es) * | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| CN120698983A (zh) | 2018-12-20 | 2025-09-26 | C4医药公司 | 靶向蛋白降解 |
| JP2022527114A (ja) | 2019-04-05 | 2022-05-30 | カイメラ セラピューティクス， インコーポレイテッド | 分解剤およびそれらの使用 |
| EP3969458A4 (en) | 2019-05-13 | 2023-05-17 | Borah, Inc. | CHEMICAL COMPOUNDS |
| CA3164832A1 (en) | 2019-12-18 | 2021-06-24 | Novartis Ag | 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| BR112022014981A2 (pt) | 2020-02-04 | 2022-09-27 | Stingray Therapeutics Inc | Inibidores de ectonucleotídeo pirofosfatase/fosfodiesterase 1 (enpp1) e métodos de uso dos mesmos |
| EP4100407A1 (en) | 2020-02-09 | 2022-12-14 | Newave Pharmaceutical Inc. | Quinuclidinone analogues as anticancer agents |
| UY39671A (es) | 2021-03-15 | 2022-10-31 | Novartis Ag | Derivados de pirazolopiridina y sus usos. |
-
2022
- 2022-03-11 UY UY0001039671A patent/UY39671A/es unknown
- 2022-03-11 PY PY202202217419A patent/PY2217419A/es unknown
- 2022-03-14 CA CA3208951A patent/CA3208951A1/en active Pending
- 2022-03-14 US US17/693,759 patent/US11787785B2/en active Active
- 2022-03-14 PE PE2023002595A patent/PE20242203A1/es unknown
- 2022-03-14 MX MX2023010827A patent/MX2023010827A/es unknown
- 2022-03-14 EP EP22711643.1A patent/EP4308562A1/en active Pending
- 2022-03-14 CR CR20230486A patent/CR20230486A/es unknown
- 2022-03-14 IL IL305931A patent/IL305931A/en unknown
- 2022-03-14 WO PCT/IB2022/052281 patent/WO2022195454A1/en not_active Ceased
- 2022-03-14 JP JP2023556474A patent/JP7659648B2/ja active Active
- 2022-03-14 TW TW111109165A patent/TW202304900A/zh unknown
- 2022-03-14 KR KR1020237034868A patent/KR102902295B1/ko active Active
- 2022-03-14 AU AU2022239950A patent/AU2022239950B2/en active Active
- 2022-03-14 NZ NZ802195A patent/NZ802195A/en unknown
-
2023
- 2023-07-21 ZA ZA2023/07290A patent/ZA202307290B/en unknown
- 2023-09-01 US US18/460,428 patent/US12172984B2/en active Active
- 2023-09-13 CL CL2023002726A patent/CL2023002726A1/es unknown
- 2023-09-13 DO DO2023000188A patent/DOP2023000188A/es unknown
- 2023-09-14 JO JOJO/P/2023/0218A patent/JOP20230218A1/ar unknown
- 2023-10-12 CO CONC2023/0013486A patent/CO2023013486A2/es unknown
- 2023-10-12 EC ECSENADI202376800A patent/ECSP23076800A/es unknown
-
2024
- 2024-09-06 US US18/826,887 patent/US12252482B2/en active Active
- 2024-11-06 US US18/939,314 patent/US20250282762A1/en active Pending
-
2025
- 2025-03-28 JP JP2025056015A patent/JP2025106341A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ZA202307290B (en) | 2024-09-25 |
| JP2025106341A (ja) | 2025-07-15 |
| AU2024278210A1 (en) | 2025-01-02 |
| US20240158374A1 (en) | 2024-05-16 |
| UY39671A (es) | 2022-10-31 |
| US20250002479A1 (en) | 2025-01-02 |
| IL305931A (en) | 2023-11-01 |
| US20250282762A1 (en) | 2025-09-11 |
| JOP20230218A1 (ar) | 2023-09-14 |
| US11787785B2 (en) | 2023-10-17 |
| WO2022195454A1 (en) | 2022-09-22 |
| AU2022239950A1 (en) | 2023-08-31 |
| US12252482B2 (en) | 2025-03-18 |
| KR102902295B1 (ko) | 2025-12-23 |
| PY2217419A (es) | 2022-09-27 |
| AU2022239950B2 (en) | 2024-09-12 |
| DOP2023000188A (es) | 2023-11-15 |
| TW202304900A (zh) | 2023-02-01 |
| CA3208951A1 (en) | 2022-09-22 |
| PE20242203A1 (es) | 2024-11-19 |
| CL2023002726A1 (es) | 2024-04-01 |
| US12172984B2 (en) | 2024-12-24 |
| MX2023010827A (es) | 2023-09-28 |
| JP2024509981A (ja) | 2024-03-05 |
| JP7659648B2 (ja) | 2025-04-09 |
| EP4308562A1 (en) | 2024-01-24 |
| NZ802195A (en) | 2025-10-31 |
| KR20230156766A (ko) | 2023-11-14 |
| US20230108325A1 (en) | 2023-04-06 |
| CO2023013486A2 (es) | 2023-11-10 |
| CR20230486A (es) | 2024-01-25 |
| BR112023018542A2 (pt) | 2023-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2022000121A (es) | Derivados de 3-(5-metoxi-1-oxoisoindolin-2-il)piperidin-2,6-diona y usos de los mismos | |
| ECSP23076800A (es) | Derivados de pirazolopiridina y sus usos | |
| ECSP24000004A (es) | Derivados de 3(1oxoisoindolin2il)piperidina2,6diona y sus usos médicos | |
| MX2016005574A (es) | Composiciones de ribosido de nicotinamida para uso topico en el tratamiento de afecciones de la piel. | |
| CO6430467A2 (es) | Péptidos útiles en el tratamiento y/o cuidado de la piel y/o cabello y su uso en composiciones cosméticas o farmacéuticas | |
| UY30481A1 (es) | Isoxazolinas sustituidas, composiciones farmaccuticas que contienen a las mismas, metodos de preparacion y usos. | |
| UY30282A1 (es) | Compuestos quimicos | |
| BR112014013140A2 (pt) | cosmética de prótese | |
| CU20110209A7 (es) | Composiciones adecuadas para el tratamiento tópico o infecciones fúngicas de la piel y unas | |
| CY1115734T1 (el) | Συνθεσεις benzenesulfonamide, μεθοδος συνθεσης τους, και χρηση αυτων στην ιατρικη | |
| AR112353A1 (es) | Compuesto de insulina acilada | |
| UY28209A1 (es) | Derivados de aminoácidos con cicloalquilo, procedimiento para su preparación y su uso como medicamentos. | |
| JP2013525342A5 (es) | ||
| AR037766A1 (es) | Compuestos triaromaticos analogos de la vitamina d, su utilizacion, composiciones farmaceuticas y cosmeticas que los comprenden y utilizacion cosmetica de dichas composiciones cosmeticas | |
| ES2703530T3 (es) | Composición cicatrizante y utilización | |
| CY1123360T1 (el) | Ενωσεις oi οποιες εχουν αντιοξειδωτικη δραση εναντι των ελευθερων ριζων και αντιφλεγμονωδη δραση, και αντιστοιχες φαρμακευτικες συνθεσεις για τη φροντιδα του δερματος | |
| MX382521B (es) | Nuevos compuestos bioaromaticos de propinilo, composiciones farmaceuticas y cosmeticas que contienen los mismos y usos de los mismos. | |
| ECSP055984A (es) | Derivados cicloalquilo que tienen grupos ácido carboxílico bioisostéricos, procesos para su preparación y su uso como composiciones farmacéuticas | |
| RU2016119040A (ru) | Способ лечения сахарного диабета второго типа и его кожных осложнений | |
| DOP2009000093A (es) | Dihidropirazolonas sustituídas para el tratamiento de enfermedades cardiovasculares y hematológicas |